{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:49:23Z","timestamp":1782388163737,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to understand the clinical characteristics of individuals who misuse over\u2010the\u2010counter (OTC) drugs in psychiatric clinical settings in Japan, and to reconsider approaches to current drug misuse prevention education and support strategies in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were obtained from\n                      <jats:italic>the 2024 Nationwide Survey on Drug\u2010Related Disorders in Psychiatric Inpatient Facilities in Japan<\/jats:italic>\n                      . Patients for whom OTC drugs were the primary substance of abuse were identified, and their demographic profiles, ICD\u201010 subcategories, and comorbid psychiatric disorders were examined. On the basis of the substance initially misused, participants were classified into three groups: illicit drugs, prescription drugs, and OTC drugs. Comparative analyses were conducted to assess clinical characteristics across these groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 389 participants were included in the analysis: 36 in the illicit drug group, 47 in the prescription drug group, and 306 in the OTC drug group. Compared with the other groups, the OTC drug group exhibited a significantly higher proportion of female patients, adolescents, and individuals enrolled in junior or senior high school. Furthermore, this group demonstrated significantly lower rates of criminal history and engagement with support or treatment services, such as self\u2010help groups, addiction\u2010focused group therapy, and psychiatric hospitalization. In contrast, the prevalence of comorbid psychiatric disorders was significantly higher in the OTC drug group compared with the other two groups. Within the ICD\u201010 subcategories, \u201charmful use\u201d was notably more frequent in the OTC drug group compared with the other groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this study indicate that OTC drug misuse has become a significant public health concern among adolescent females in Japan. The present findings underscore the necessity of reconsidering existing drug misuse prevention education and support frameworks, which have traditionally been oriented toward illicit substances.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.70108","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:45:09Z","timestamp":1774842309000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics of Over\u2010The\u2010Counter Drug Misusers in Psychiatric Practice in Japan: Comparison by Type of Drug Misused for the First Time"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-2859","authenticated-orcid":false,"given":"Soichiro","family":"Omiya","sequence":"first","affiliation":[{"name":"Clinical Psychology, Graduate School of Education Joetsu University of Education  Niigata Japan"},{"name":"Department of Drug Dependence Research National Institute of Mental Health, National Center of Neurology and Psychiatry  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1690-6793","authenticated-orcid":false,"given":"Yuko","family":"Tanibuchi","sequence":"additional","affiliation":[{"name":"Department of Drug Dependence Research National Institute of Mental Health, National Center of Neurology and Psychiatry  Tokyo Japan"},{"name":"Chiba Hospital  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-8663","authenticated-orcid":false,"given":"Takashi","family":"Usami","sequence":"additional","affiliation":[{"name":"Department of Drug Dependence Research National Institute of Mental Health, National Center of Neurology and Psychiatry  Tokyo Japan"},{"name":"Fukuoka Prefectural Psychiatric Center Dazaifu Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-6230","authenticated-orcid":false,"given":"Takuya","family":"Shimane","sequence":"additional","affiliation":[{"name":"Department of Drug Dependence Research National Institute of Mental Health, National Center of Neurology and Psychiatry  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7076-2161","authenticated-orcid":false,"given":"Toshihiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Drug Dependence Research National Institute of Mental Health, National Center of Neurology and Psychiatry  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.12.2.88"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00416.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11050"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7033.758"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2011.615002"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12415"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00350-7"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10100736"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.657397"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00767"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.572245"},{"key":"e_1_2_13_13_1","volume-title":"World Drug Report 2021\u2014COVID\u201019 and Drugs: Impact Outlook","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2021"},{"key":"e_1_2_13_14_1","volume-title":"Nationwide Survey on the Actual Conditions of Drug\u2010Related Mental Disorders in Psychiatric Hospitals in Japan","author":"Matsumoto T.","year":"2012"},{"key":"e_1_2_13_15_1","volume-title":"Nationwide Survey on the Actual Conditions of Drug\u2010Related Mental Disorders in Psychiatric Hospitals in Japan","author":"Matsumoto T.","year":"2024"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15332640.2020.1824842"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.735563"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06368-w"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2016.06.008"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-023-01353-w"},{"issue":"12","key":"e_1_2_13_21_1","first-page":"1184","article-title":"Current Situation and Clinical Characteristics of Sedative\u2010Related Disorder Patients in Japan: A Comparison With Methamphetamine\u2010Related Disorder Patients","volume":"113","author":"Matsumoto T.","year":"2011","journal-title":"Seishin Shinkeigaku Zasshi"},{"key":"e_1_2_13_22_1","volume-title":"Suicide Situation in 2024","author":"Suicide Prevention Promotion Office, Ministry of Health, Labour and Welfare; Life Safety Planning Division, Life Safety Bureau, National Police Agency","year":"2025"},{"key":"e_1_2_13_23_1","volume-title":"Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009","author":"Johnston L. D.","year":"2010"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2005.08.010"},{"key":"e_1_2_13_25_1","volume-title":"National Survey of High School Students on Drug Use and Lifestyle","author":"Shimane T.","year":"2021"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200401000-00017"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-007-0273-1"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2008.01879.x"},{"issue":"7","key":"e_1_2_13_29_1","first-page":"960","article-title":"Current Situation and Measures Against Abuse of Over\u2010The\u2010Counter Medicines by Children","volume":"57","author":"Matsumoto T.","year":"2025","journal-title":"Japanese Journal of Pediatric Medicine"},{"key":"e_1_2_13_30_1","volume-title":"Nationwide Survey on the Actual Conditions of Drug\u2010Related Mental Disorders in Psychiatric Hospitals in Japan","author":"Matsumoto T.","year":"2014"},{"issue":"6","key":"e_1_2_13_31_1","first-page":"475","article-title":"Risk Factors of Near\u2010Fatal Deliberate Self\u2010Harm Behavior in Self\u2010Cutting Patients: A Three\u2010Year Follow\u2010Up Study at a Psychiatric Clinic","volume":"110","author":"Matsumoto T.","year":"2008","journal-title":"Seishin Shinkeigaku Zasshi"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4997"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1665182"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.70108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:23:25Z","timestamp":1782386605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.70108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/npr2.70108"],"URL":"https:\/\/doi.org\/10.1002\/npr2.70108","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"2025-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70108"}}